stockportfolio.pro
Stocks / HCM vs MRVI
HCM vs MRVI
HUTCHMED (China) Limited and Maravai LifeSciences Holdings, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| HUTCHMED (China) Limited (HCM) | Maravai LifeSciences Holdings, Inc. (MRVI) | |
|---|---|---|
| Market cap | $1.8B | $1.9B |
| Revenue (latest FY) | $548.51M | $185.74M |
| Net income (latest FY) | $456.91M | $-130.77M |
| Revenue growth (5y CAGR) | 8.8% | -8.1% |
| Net margin | 83.3% | -70.4% |
| Return on equity | 36.9% | -61.6% |
| P/E ratio | 4.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 3 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HCM — free Open MRVI — freeFrequently asked questions
Which is bigger, HCM or MRVI?
Maravai LifeSciences Holdings, Inc. is larger by market capitalization — $1.9B versus $1.8B.
Which grows faster, HCM or MRVI?
Over the last five fiscal years, HUTCHMED (China) Limited grew revenue faster — 8.8%/yr versus -8.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.